## Business Summary

International Isotopes Inc. (INIS) operates as a highly specialized supplier providing radioactive materials used mainly for medical procedures, scientific research, and calibrating sophisticated measuring equipment. Their core business model involves producing, packaging, and safely delivering these unique, regulated products, often catering to time-sensitive diagnostic needs, such as materials for PET scans. INIS is strictly a business-to-business (B2B) supplier; their customers are typically hospitals, diagnostic laboratories, research institutions, and large equipment manufacturers. They serve both domestic and international markets. Revenue is generated from the sale of these short-lived, specialty chemicals and high-precision calibration standards, which are essential for many modern healthcare and industrial processes.

---

## Business Model Risk

The business faces significant risks primarily due to its dependency on a heavily regulated environment, governed by numerous strict agencies. A key near-term risk is supply chain fragility: the company relies on a limited number of sources for the specialized raw radioactive materials. Any disruption or unexpected price surge in these materials can immediately stop production, harming short-term earnings. Furthermore, maintaining and updating specialized nuclear licenses requires substantial capital, and minor changes in regulatory standards can dramatically raise operating costs. The major long-term risk is technological obsolescence. If new, non-radioactive imaging technologies are developed, the overall demand for INIS's core isotope products could slowly shrink, eroding their market position. Historically, this industry has suffered from global supply crises caused by unexpected shutdowns of key production reactors, demonstrating how sensitive the market is. This historical fragility remains a major concern because, given the high fixed costs of operating their specialized facilities, even minor production downtime can severely damage profitability.

---

## Company History

International Isotopes Inc. (INIS) is a company specializing in the highly technical field of nuclear medicine, which uses tiny amounts of radioactive materials (radioisotopes) for diagnosing and treating various diseases.

Here is a simple history lesson to explain their journey:

### **Inception and Core Purpose**

1.  **Founding (1995):** International Isotopes Inc. (INIS) was founded in 1995 and is headquartered in Idaho Falls, Idaho.
2.  **Core Mission:** The company was established to develop, produce, and sell a wide range of products centered on radioisotopes, primarily supporting nuclear medicine for diagnosis and therapy.
3.  **Initial Products:** Their initial offerings included products like generic sodium iodide I-131, a key radiopharmaceutical used for treating thyroid cancer and hyperthyroidism, as well as calibration and reference standards for the nuclear medicine and industrial sectors (known today under the RadQual brand).

### **Early Headwinds and Strategic Pivots**

4.  **Early Financial Pressure (2000):** Early on, the company faced financial challenges, leading to a major cost-saving move where they shut down the operations of their linear accelerator, a large, expensive piece of equipment, and reduced their workforce.
5.  **A Regulatory Crisis (2019):** A significant setback occurred in 2019 due to a radiological contamination event in Seattle, which stemmed from a service provided by their field services unit.
6.  **Addressing the Crisis:** The Nuclear Regulatory Commission (NRC) issued two violations, which prompted INIS to immediately cease all field service operations and ultimately amend its license to remove authorization for those activities, focusing the business elsewhere.
7.  **Focusing on Healthcare:** By officially discontinuing the field service segment, which had experienced the contamination incident, the company was able to concentrate its resources and efforts on its growing healthcare-related product lines.

### **Major Headwinds and Innovative Solutions**

8.  **The Cobalt-57 Shortage Headwind:** In 2023 and early 2024, the company's Nuclear Medicine Standards segment was significantly impacted by a global shortage of Cobalt-57, a critical isotope for their calibration standards used in diagnostics.
9.  **Solving the Supply Problem:** The company worked to resolve this bottleneck by streamlining its operations and securing approvals from the U.S. Food and Drug Administration (FDA) for new, reliable raw material suppliers.
10. **Financial Turnaround:** Resolving this major supply issue resulted in a quick recovery, with a significant revenue surge (99%) in their calibration segment and a 136% improvement in their key financial metric (EBITDA) in the first quarter of 2025.
11. **Strategic Diversification (RadVent):** To build a more resilient business, INIS strategically diversified by launching a new Medical Devices segment, the RadVent brand, which includes products like the *Swirler®* and *Tru-Fit™ Mouthpiece* used to enhance precision in nuclear imaging.

### **Current Status and Future Goals**

12. **Major Tailwinds - US Manufacturing Dominance:** A significant competitive advantage is that INIS remains the only domestic U.S. manufacturer of high-activity Cobalt-60 sealed-source products and the only domestic manufacturer of their key generic sodium iodide I-131 drug product.
13. **Global Expansion through Partnership:** To expand their reach, the company established a manufacturing joint venture called Radnostix China with Alpha Nuclides to bring their calibration products into the Chinese market.
14. **Focus on Theranostics and Nuclear Medicine:** The ultimate goal is to capitalize on the growing nuclear medicine market, which includes *theranostics*—the combination of therapeutics (treatment) and diagnostics (imaging) using radioisotopes.
15. **Present-Day Focus (2025):** Today, INIS is focused on operational improvements, finalizing the launch of its new RadQual PET and RadVent medical devices, and maximizing sales of its core products, including the specialized Cobalt products, which are vital for medical and industrial use.

---

## Moat Analysis

The analysis of International Isotopes Inc. (INIS) points to a moat built primarily on **Regulatory Barriers**, **Specialized Infrastructure**, and a position as a **Domestic Sole-Source Supplier** for critical medical and industrial materials.

Here is an analysis of the company's competitive advantages and market position:

---

### Analysis of the Moat for International Isotopes Inc. (INIS)

#### 1. Unique Differentiation and Market Position

*   **Regulatory Barrier (Licenses):** A primary moat is the complex regulatory environment of the nuclear industry; the company holds multiple, hard-to-acquire **U.S. Nuclear Regulatory Commission (NRC) licenses** for handling, production, and distribution of radioisotopes. These licenses create a high barrier to entry that is time-consuming and expensive for competitors to replicate.
*   **Domestic Sole-Source Advantage:** INIS is the **only domestic U.S. manufacturer of high-activity Cobalt-60 sealed-source products**, which are critical for radiation therapy and industrial applications. Similarly, their FDA-approved generic **sodium iodide I-131 drug product** (used for thyroid cancer treatment) is the only generic of its kind manufactured in the U.S. This unique domestic supply position offers a competitive edge, especially during global supply shortages.
*   **Specialized Infrastructure:** The company's facilities in Idaho and New Mexico, along with its specialized equipment for producing radioisotopes and fabricating sealed sources, represent a significant asset that requires substantial capital and technical expertise to establish.

#### 2. Pricing Power and Customer Relationships

*   **Pricing Power:** The company has reported a healthy gross profit percentage (e.g., 62% in 2024), which suggests it has some degree of pricing power in its specialized niches. This is likely due to the limited number of suppliers for highly critical and regulated products like I-131 and Cobalt-60.
*   **Sticky and Recurring Customers:** The customer base consists largely of nuclear pharmacies, hospitals, imaging centers, and industrial companies that need radioisotopes for diagnostics, therapy, and calibration standards (RadQual brand).
    *   **Recurring Demand:** Products like calibration standards and the I-131 drug are essential, recurring consumables.
    *   **High Switching Costs:** Switching suppliers for mission-critical, regulated medical and industrial products carries a high risk and high cost of requalification, making customer contracts and relationships sticky.
    *   The Cobalt Products segment specifically reports strong customer relationships and repeat business, though revenue can be volatile based on the timing of large orders.

#### 3. Historical Growth and R&D/Innovation

*   **Reason for Growth:** The company's most significant recent growth has been driven by the commercial launch and increasing demand for its **FDA-approved generic sodium iodide I-131 drug product**, which provided a strong new revenue stream in the medical theranostics space. Growth has also been fueled by increased sales of Cobalt-60 materials and the resolution of prior supply bottlenecks.
*   **Investment in R&D and Innovation:** INIS actively invests in R&D and new product development to maintain its edge.
    *   **Product Diversification:** They are actively diversifying into the **Medical Devices segment** (e.g., the EasyFill Automated Capsule System and the RadVent brand of products) and forming strategic distribution partnerships for international radiopharmaceutical technology.
    *   **Strategic Projects:** The company is pursuing the development of a domestic, non-reactor-based facility for producing molybdenum-99 (Mo-99), a critical diagnostic isotope, aiming to reduce U.S. reliance on foreign sources.
    *   **Constant Innovation:** The nature of the nuclear medicine and theranostics market is dynamic; to stay ahead, the company must constantly innovate by developing new products and securing distribution agreements for cutting-edge radiopharmaceuticals, like Terbium-161 (Tb-161).

#### 4. Vulnerability to Displacement and Network Effects

*   **Displacement by Capital:** While large capital is required to compete, INIS is **not easily displaced by a competitor with "more capital alone"** due to the formidable **regulatory and technical barriers to entry**. An immensely capitalized competitor would still need to spend years obtaining the necessary NRC licenses, FDA approvals, and building the specialized, validated facilities and supply chain.
*   **Network Effects:** Direct network effects (where each user makes the product more valuable to other users) are not a core driver for a specialized producer like INIS. However, they have built an advantage through their **distribution and partnership network**, such as a joint venture in China and North American distribution agreements for international technology, which makes their suite of products more accessible and comprehensive for customers. This established distribution channel and partner network make it a more valuable partner and supplier.

---

## Catalyst Analysis

The following is an analysis of the catalysts for International Isotopes Inc. (INIS), based on recent news, financial reports, and investor releases.

### Catalysts for International Isotopes Inc. (INIS)

#### Near-Term Catalysts (Within the next 6-12 months)

1.  **Increased Seasonal and High-Activity Cobalt Sales:** Management expects a performance rebound in the latter half of 2025 due to the seasonal increase in sales of their Cobalt products, as well as existing orders planned for manufacturing.
2.  **Full Recovery of Nuclear Medicine Standards Segment:** The significant revenue surge (99% in the first six months of 2025) in this segment, following the resolution of the global Cobalt-57 isotope shortage in late July 2024, should continue to drive top-line growth.
3.  **Launch of New Product Lines:** The company is focused on finalizing and launching new products, including the RadQual PET product line and the new RadVent brand of medical devices, which are expected to start generating revenue by the fourth quarter of 2025.
4.  **Operational Risk Mitigation and Efficiency:** INIS has applied to the FDA for approval of additional suppliers for their Theranostics segment to mitigate future raw material outages, which caused a temporary sales decline in Q1 2025. Management is generally focused on operational improvements.

#### Long-Term Catalysts (Beyond 12 months)

1.  **Strategic Market Position in Key Isotopes:** INIS is the sole domestic U.S. manufacturer and supplier of high activity Cobalt-60 sealed-source products and the only domestic manufacturer of generic sodium iodide I-131 radiopharmaceutical drug, securing a strategic position in critical markets.
2.  **Expansion into New Therapeutic Isotopes:** The company has entered into a U.S. distribution agreement for Terbium-161 (Tb-161), a cutting-edge radionuclide that could serve as a complement or alternative to Lutetium-177 in targeted radiotherapy treatments.
3.  **Growth in the Theranostics Market:** The Theranostics Products segment is expected to see continued growth, driven by the ongoing demand for generic sodium iodide I-131 used to treat thyroid cancer and I-131 theranostic Active Pharmaceutical Ingredient (API).
4.  **Geographic Expansion via Joint Venture:** The launch of a manufacturing joint venture, Radnostix China, with Alpha Nuclides, aims to bring INIS and RadQual products into the Chinese market, opening a new avenue for international sales.
5.  **Operational Footprint Expansion:** A strategic land acquisition and a new facility lease agreement completed in early 2025 signal an expansion of the company's operational footprint to support future growth and increased production capacity.

#### Management's Stated Strategy and Outlook

*   **Near-Term Focus (Q1/Q2 2025 Earnings):** President & CEO Shahe Bagerdjian stated, "For the rest of 2025, we remain focused on operational improvements and finalizing product launches," expecting to "realize the fruits of our labor in the 2nd half of 2025" due to seasonal Cobalt sales and the new RadQual PET and RadVent products.
*   **Financial Discipline:** The company's strategy led to a 136% improvement in Non-GAAP EBITDA in Q1 2025, reversing a previous loss, which signals a focus on profitability and operational efficiency.
*   **Mitigating Supply Chain Risks:** Management highlighted the effort to secure FDA approvals for additional suppliers to mitigate future raw material disruptions, particularly in the Theranostics segment.

---

## Management Record

The management analysis for International Isotopes Inc. (INIS) for an investor is as follows:

### 1. Current Management: Shahe Bagerdjian (CEO & President)

*   **Appointment and Tenure:** Shahe Bagerdjian was appointed CEO effective September 1, 2023, and has served as President since April 2023, marking a recent transition in top leadership.
*   **Compensation:** The CEO's total compensation (USD $429.70K) is reported to be about average for similarly sized companies in the US market, and his pay has been consistent with company performance over the past year.
*   **Insider Confidence:** The CEO, Shahe Bagerdjian, along with the Chief Financial Officer (W. Cox) and Chairman of the Board (Christopher Grosso), has recently engaged in insider stock purchases, indicating management confidence.

### 2. Track Record and Performance

*   **Financial Momentum:** The current management is building on a period of strength, as the previous CEO stated the company was in its strongest financial position in its history at the time of the 2023 leadership change.
*   **Recent Delivery on Promises (Q1 2025):** Management has delivered tangible financial improvements, including a 12% growth in sales and a 136% increase in non-GAAP EBITDA for the first quarter of 2025 compared to the prior year.
*   **Operational Execution:** The team has proactively managed supply chain risks, such as applying for FDA approval for additional raw material suppliers to mitigate future outages that previously impacted the Theranostics segment.
*   **Addressing Challenges:** They successfully navigated a prolonged global shortage of the Cobalt-57 isotope in 2024, restoring supply by late July of that year, which led to a partial recovery of backlogged sales.

### 3. Historical Management & Transition

*   **Long-Term CEO:** Steve Laflin was the longstanding CEO, serving the company for 22 years (since 2001) before stepping down in August 2023.
*   **Value Delivery (Previous Management):** During Laflin's tenure, the company achieved its highest-ever revenue of \$12.3 million in fiscal year 2023 and reported positive cash flow from operating activities.
*   **Orderly Transition:** The transition to the new CEO, Shahe Bagerdjian, was orderly, with Mr. Laflin remaining on the Board of Directors and continuing to consult for the company.
*   **Board Experience:** The Board of Directors as a whole is described as seasoned and experienced, with an average tenure of 15.9 years.

### 4. Future Strategy and Vision

*   **Strategic Focus:** The current vision is focused on a multi-pronged approach: sustained operational improvements, new product launches, and market share expansion.
*   **Product Diversification (Key Decision):** A major new strategic decision is the expansion into a new **Medical Devices** business segment, under the **RadVent** brand, with commercialization of products like the Swirler® and Tru-Fit™ mouthpiece anticipated for 2025.
*   **Market Expansion:** The strategy includes a geographic expansion, with plans to grow sales in Asia (via a manufacturing joint venture in China) and Latin America.
*   **Partnerships:** A key strategic move includes an exclusive North American distribution partnership with SCINTOMICS Molecular, Applied Theranostics Technologies GmbH (ATT) for their state-of-the-art radiopharmaceutical synthesis modules.
*   **Expected Future Performance:** Management anticipates further improved results in the second half of 2025 due to new product launches, including RadQual PET products, and a seasonal increase in Cobalt product sales.

---

## Management Incentive

Based on the analysis of public filings and ownership data, here is an analysis of the management incentives and compensation for International Isotopes Inc. (INIS).

### **Management Incentive and Compensation Analysis**

#### **1. Insider Ownership (Incentive Alignment)**

*   **High Insider Ownership:** The high level of insider ownership is a strong indicator of management's incentive alignment with shareholders, as company insiders own approximately **45.74%** of the company's shares.
*   **Shareholder Interest Alignment:** This high percentage means that a significant portion of the managers' and directors' personal wealth is directly tied to the company's stock price performance. Consequently, management has a substantial personal financial incentive to act in the long-term interest of all shareholders by increasing the value of the stock.
*   **Low Institutional Ownership:** Institutional ownership is reported to be very low, at approximately 0% of shares, which further highlights the concentration of ownership among insiders and retail shareholders.

#### **2. Compensation Structure**

*   **CEO Compensation:** The total compensation for the CEO is approximately **$429,702**, which is noted as being consistent with the company's performance over the past year and is about average for companies of a similar size in the US market.
*   **Equity Awards for Directors:** The compensation structure for non-employee directors includes the potential for **stock awards** and **option awards** from the company's equity compensation plans. This use of equity ties a portion of their compensation directly to share price appreciation, aligning their interests with shareholders.
*   **Cash-Based Director Pay:** Directors generally do not receive retainer fees, but they are reimbursed for expenses and one director receives an hourly rate for service, which may introduce a non-performance-based cash component to the overall compensation.

#### **3. Conclusion on Incentives**

The management and directors of International Isotopes Inc. appear to have a strong financial incentive to act in the interest of the shareholders, primarily due to their exceptionally high insider ownership.

*   **Aligned with Shareholders:** The major incentive driver is the **45.74% insider ownership**, which provides a powerful link between management's net worth and the stock price. This structure discourages short-term self-serving decisions that could harm the long-term stock value.
*   **Incentive Structure Support:** The use of **equity awards** (options and stock) as a component of the compensation structure for both executives and directors further reinforces this alignment by linking a portion of their pay to the creation of shareholder value.
*   **Risk of Pockets-Lining:** While the CEO's salary is considered average for the company's size, and the compensation is noted as consistent with performance, any incentive-based compensation that lacks rigorous, long-term performance metrics could still allow for short-term gains. However, the massive equity stake held by insiders serves as a significant mitigating factor against simply "lining their own pockets" at the expense of stock value.

---

## Price History

Here is an analysis of the price history and technical situation for International Isotopes Inc. (INIS).

1.  **Current Position Relative to 52-Week Range:** The stock's last closing price of $0.0910 (as of November 7, 2025) is significantly above its 52-week low of $0.0300. It is approximately **203.33%** above its 52-week low.

2.  **Is it Trading Low Based on Technical Analysis?** The stock is **not** currently trading low based on most technical indicators, as the overall technical rating is a "Buy" or "Strong Buy" on a one-week and one-month basis, according to one major technical analysis platform. While some oscillators show a "Sell" trend, the presence of a "buy signal" from the long-term moving average suggests a positive long-term outlook.

3.  **Recent Significant Price Movements (Up Bigly):** The stock has experienced a substantial upward movement, rising by **82%** over a recent two-week period. Since the beginning of the year, the stock has increased by approximately **164.5%** from its price of $0.0344.

4.  **Explanation for Recent Gains:** A contributing factor to the positive sentiment and gains may be the reported insider activity, which shows "Positive" sentiment driven by high-impact open-market purchases. The company has also announced fiscal results for the first and second quarters of 2025.

5.  **Technical Support and Resistance:** The stock finds support from accumulated volume at $0.0900, while it would meet resistance from the short-term Moving Average at approximately $0.0968. This puts the stock just above its support level.

---

## Long Thesis

International Isotopes (INIS) is positioned to thrive because it is an essential, highly protected, specialized supplier for the growing field of nuclear medicine. The company holds unique U.S. government licenses (a massive barrier to entry) that make it the only domestic source for several mission-critical products, such as materials used for treating thyroid cancer and high-activity radiation sources. In the near term, the company has fixed recent supply chain bottlenecks that damaged sales, allowing its core business to recover strongly and boost profits immediately. This recovery is coupled with new product launches—like specialized medical devices and new calibration standards—which will start generating new revenue in late 2025. Long term, INIS benefits from two trends: the massive growth in combined diagnostic and therapeutic treatments (theranostics) using radioactive materials, and its strategic moves to dominate the U.S. market while expanding into high-growth international markets like China. Management's recent success in boosting profitability and their high insider ownership confirm their strong motivation to execute this growth strategy.

---

## Long Thesis Assumptions

This positive outlook relies on four key factors: 1) The global market for nuclear medicine (especially theranostics) must continue its rapid growth trajectory. 2) The new products being launched (RadVent medical devices, RadQual PET standards) must achieve market acceptance and deliver substantial sales, fulfilling management's revenue targets. 3) The newly stabilized supply chains for critical raw materials must remain reliable, avoiding the disruptions that hurt the company previously. 4) The company must successfully execute its geographic expansion plans, especially the new joint venture to penetrate the Chinese market effectively.

---

## Bear Case Scenario

The long thesis for International Isotopes Inc. (INIS) presents a very optimistic view, but the recent operational and financial details suggest significant holes, execution risks, and vulnerabilities that form a strong bear case.

### **Bear Case Thesis for International Isotopes Inc. (INIS)**

The bullish narrative is built on projected growth and 'fixed' operational issues, but current financial results show the company remains financially fragile and operations are susceptible to recurring risks. INIS is a microcap company where future success hinges on the successful launch of multiple new products and complex international ventures, all while operating near a net loss. This introduces high execution risk that is not adequately factored into the bullish scenario.

***

### **Critique and Flaws in the Long Thesis**

1.  **The Claim of "Strongly Boost Profits Immediately" is Not Supported by Financials.**
    The company reported a net loss of over \$112,000 in Q1 2025, and while Non-GAAP EBITDA was a small positive, the overall financial status is not one of a company "strongly boost[ing] profits immediately." The improvement is marginal, not a strong recovery.

2.  **Supply Chain Vulnerability is Ongoing, Not "Fixed."**
    The core assumption of "fixed recent supply chain bottlenecks" is directly contradicted by a two-week raw material outage in Q1 2025, which caused the key Theranostics segment revenue to decline by 6%. This demonstrates that reliance on a single-source supplier is a systemic vulnerability, and the company is still taking reactive steps (seeking additional FDA-approved suppliers) to mitigate an existing risk.

3.  **Future Revenue is Dependent on High-Risk, Unproven Product Launches.**
    The expected boost from new products like RadVent medical devices and new RadQual PET standards is still largely forward-looking, with commercialization and revenue realization not fully expected until the second half or even the fourth quarter of 2025. The initial Q1 2025 Medical Device segment revenue was minimal (\$52,630), meaning the revenue is based on future product success, not proven current market acceptance.

4.  **"Massive Barrier to Entry" is Offset by Operational Scale and Product Generic Status.**
    While INIS is the only domestic U.S. manufacturer of high-activity Cobalt-60 sealed sources, a core product in the Theranostics segment is generic sodium iodide I-131. This is a commodity product with a supply chain susceptible to disruption, turning the *reliance* on a specific raw material into a major operational risk, rather than a defensible advantage.

5.  **The Geographic Expansion Plan (China) Carries Significant Execution and Regulatory Risk.**
    The new joint venture in China is still in its initial phase of distribution, and the plan to manufacture locally is subject to future regulatory hurdles, specifically the registration and approval from the China Food and Drug Administration (CFDA). The success of this long-term play depends on navigating complex foreign regulatory and business environments.

6.  **The Company's Stock is Traded on the OTCQB.**
    As an OTCQB-listed company, INIS may face limitations in investor liquidity and institutional interest, which can hinder capital-raising and make the stock price more volatile and susceptible to shifts in sentiment than stocks traded on major exchanges.

7.  **Management's Focus is Spread Across Multiple Disparate Initiatives.**
    The growth strategy relies on succeeding in five distinct business segments (Theranostics, Cobalt, Nuclear Medicine Standards, Medical Devices, and Fluorine Products) and executing three simultaneous major initiatives (supply chain fixes, new product commercialization, and a complex China JV). This diverse focus and high number of simultaneous ventures increase the overall risk of execution failure due to limited resources for a company of this size.

---

## Next Steps

Based on the comprehensive analysis you've provided, which details the business, moat, catalysts, and management, the most significant gaps lie in quantifying the financial upside of the catalysts, validating the segment-level profitability, and understanding the competitive landscape of their "sole-source" products.

Here are the important questions still left unanswered and the next steps to investigate:

### **Next Steps to Investigate**

1.  **Segment-Specific Profitability and Margin Trends**
    *   **Question:** What are the **Gross Margins** and **Operating Income** for each core business segment (Theranostics, Nuclear Medicine Standards, Cobalt Products)?
    *   **Why:** We know the company has a *healthy gross profit percentage* overall, but need to confirm if the high-growth segments (like Nuclear Medicine Standards, up 73% in Q1 2025) are high-margin, or if the "sole-source" Theranostics segment carries the most profit. This will validate the moat's pricing power.
    *   **Search Query:** `International Isotopes Inc. (INIS) segment gross margin`

2.  **Competitive Landscape and Market Validation**
    *   **Question:** Who are the **primary competitors** in the generic sodium iodide I-131 (Theranostics) and Cobalt-60 sealed source markets? How is INIS's product differentiated beyond its domestic sole-source status?
    *   **Why:** The Bear Case views the I-131 as a commodity. We need to know who the international and non-generic domestic competitors are and how INIS's pricing compares to validate whether the regulatory moat translates into sustainable pricing power or simply supply-chain resilience.
    *   **Search Query:** `International Isotopes Inc. (INIS) I-131 competitors market share`

3.  **Quantifying the New Catalyst Upside**
    *   **Question:** What is the estimated **Total Addressable Market (TAM)** for the new product lines: **RadQual PET calibration standards** and **RadVent medical devices**? Are there any initial revenue forecasts provided by management for these segments beyond late 2025?
    *   **Why:** The bullish thesis heavily relies on the success of these new launches. Without a market size estimate, the potential growth is speculative. We need to put a dollar figure on the expected "fruits of our labor" management mentioned.
    *   **Search Query:** `market size PET calibration standards` and `International Isotopes RadVent revenue forecast`

4.  **China Joint Venture (JV) Execution Risk**
    *   **Question:** What is the **current regulatory status** of the Radnostix China joint venture with Alpha Nuclides? Has the JV secured initial **CFDA/local regulatory approvals** required to begin local manufacturing and sales?
    *   **Why:** The China JV is a complex, long-term geographic expansion. Failure to navigate the foreign regulatory environment (a key Bear Case risk) would negate a major long-term catalyst.
    *   **Search Query:** `Radnostix China CFDA approval status`

5.  **Tb-161 Distribution Deal Specifics**
    *   **Question:** What are the specific **financial terms** of the Terbium-161 (Tb-161) distribution agreement with TerThera? Is it an exclusive agreement, and what is the expected **sales ramp or revenue share**?
    *   **Why:** This is a cutting-edge therapeutic isotope. The financial impact to INIS will depend heavily on whether they are simply a logistics provider or a key partner with a favorable profit-sharing arrangement.
    *   **Search Query:** `International Isotopes Terbium-161 distribution agreement financial terms`